Cart
sales@molnova.com
ZINC05007751
CAS No. 591239-68-8
ZINC05007751( —— )
Catalog No. M28948 CAS No. 591239-68-8
ZINC05007751 is an effective inhibitor of NIMA-related kinase NEK6 (IC50 = 3.4 μM). ZINC05007751 is very selective against NEK1 and NEK6 with no significant activity observed against NEK2, NEK7, and NEK9.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 70 | In Stock |
|
| 5MG | 116 | In Stock |
|
| 10MG | 187 | In Stock |
|
| 25MG | 353 | In Stock |
|
| 50MG | 555 | In Stock |
|
| 100MG | 792 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameZINC05007751
-
NoteResearch use only, not for human use.
-
Brief DescriptionZINC05007751 is an effective inhibitor of NIMA-related kinase NEK6 (IC50 = 3.4 μM). ZINC05007751 is very selective against NEK1 and NEK6 with no significant activity observed against NEK2, NEK7, and NEK9.
-
DescriptionZINC05007751 is an effective inhibitor of NIMA-related kinase NEK6 (IC50 = 3.4 μM). ZINC05007751 is very selective against NEK1 and NEK6 with no significant activity observed against NEK2, NEK7, and NEK9.(In Vitro):In ovarian cancer cells PEO1, ZINC05007751 induced perturbation of the cell cycle. ZINC05007751 showed synergism with Cisplatin, resulting in a significant reduction of Cisplatin IC50 from 7.9 to 0.1 μM, with a combination of ZINC05007751 (44 μM) + Cisplatin (10 μM) exhibiting the greatest synergistic effect. ZINC05007751 (6 μM-190 μM; 24 hours) inhibited the growth of MDA-MB-231, PEO1, NCI-H1299, and HCT-15 with IC50 below 100 μM.
-
In VitroZINC05007751 (6 μM-190 μM; 24 hours) inhibits the growth of MDA-MB-231, PEO1, NCI-H1299 and HCT-15 with IC50 below 100?μM.ZINC05007751 induces perturbation of PEO1 cell cycle.ZINC05007751 (ovarian cancer cells PEO1) shows synergism with Cisplatin, resulting in a significant reduction of Cisplatin IC50 from 7.9 to 0.1??μM, with combination ZINC05007751 (44?μM)?+?Cisplatin (10?μM) exhibiting the greatest synergistic effect. Cell Cytotoxicity Assay Cell Line:MDA-MB-231, PEO1, NCI-H1299 and HCT-15 cells Concentration:6 μM-190 μM Incubation Time:24?hours Result:Inhibited the growth of MDA-MB-231, PEO1, NCI-H1299 and HCT-15.
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
RecptorATX (autotaxin)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number591239-68-8
-
Formula Weight304.305
-
Molecular FormulaC18H12N2O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 8.33 mg/mL (27.37 mM)
-
SMILESCC1=C(C#N)C(O)=NC(=O)\C1=C/c1ccc(o1)-c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.LEE, Dae Yon, et al. NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME. Patent O2018212534A1
molnova catalog
related products
-
2-Aminooctadecane-1,...
Phytosphingosine is a natural product.
-
PAF (C16)
PAF (C16) is a potent MAPK and MEK/ERK activator that induces increased vascular permeability. PAF (C16) (PAF (C16)) is a platelet-activating factor, a phospholipid-derived mediator and a ligand for PAF G protein-coupled receptor (PAFR). PAF (C16) has shown anti-apoptotic and anti-inflammatory activity in vitro, inhibiting Caspase-dependent apoptosis by interacting with its receptor (PAF-R) to perform cell signaling.
-
BI-2865
BI-2865 is a none-covalent pan-KRAS Inhibitor. BI-2865 binds to WT, G12C, G12D, G12V and G13D mutant KRAS with KDs of 6.9, 4.5, 32, 26, 4.3 nM respectively.
